OverviewSuggest Edit

Rallybio is a clinical-stage biotechnology company developing drugs with the main focus on antibodies, small molecules, and engineered proteins. It develops the anti-HPA-1a antibody RLYB211 and RLYB212 therapies for patients with fetal and neonatal alloimmune thrombocytopenia (FNAIT).
TypePublic
Founded2018
HQNew Haven, CT, US
Websiterallybio.com

Latest Updates

Employees (est.) (Jun 2021)28
Share Price (Oct 2021)$15.6(-3%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Rallybio

Jeffrey Fryer

Jeffrey Fryer

Co-Founder and Chief Financial Officer
Steve Uden

Steve Uden

Co-Founder and COO
Show more

Rallybio Office Locations

Rallybio has offices in New Haven and Farmington
New Haven, CT, US (HQ)
234 Church Street, Suite 1020
Farmington, CT, US
400 Farmington Avenue, Suite R2818
Show all (2)

Rallybio Financials and Metrics

Rallybio Revenue

Market capitalization (13-Oct-2021)

511.8m

Closing stock price (13-Oct-2021)

15.9
Rallybio's current market capitalization is $511.8 m.
Show all financial metrics

Rallybio Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Rallybio Online and Social Media Presence

Embed Graph

Rallybio Blogs

Rallybio Corporation Reports Second Quarter 2021 Financial Results and Recent Business Highlights

- Completed initial public offering for $92.7 million of gross proceeds - - Clinical proof-of-concept data for RLYB211 for the prevention of FNAIT was presented at the ISTH Virtual Congress ; Additional Phase 1/2 data expected in 4Q 2021 - - On-track to initiate Phase 1 studies of RLYB212, in

COWEN Investor Conference

Rallybio will be participating in one-on-one meetings during the upcoming Cowen 41st Annual Health Care Conference, a virtual event taking place March 1-4, 2021.

SVB Leerink 10th Annual Global Healthcare Conference

Rallybio will be participating in one-on-one meetings during the upcoming SVB Leerink 10th Annual Global Healthcare Conference, a virtual event taking place February 22-26, 2021.

Steven Tuch Joins Rallybio to Lead Corporate Development

NEW HAVEN, CT, January 21, 2021 – Rallybio LLC, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Steven Tuch to lead the Company’s corporate d…

Rallybio to Present at the 3rd Annual Evercore ISI HealthCONx Conference

NEW HAVEN, Conn., November 24, 2020 – Rallybio, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that Martin Mackay, Chief Executive Officer, Jeff Fryer, Ch…

Rallybio Announces First-in-Human Dosing in RLYB211 Phase 1/2 Study

RLYB211 is in Clinical Development for the Prevention of FNAIT, a Potentially Life-Threatening Rare Disorder that Impacts Fetuses and Newborns NEW HAVEN, Conn., November 10, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming th…
Show more

Rallybio Frequently Asked Questions

  • When was Rallybio founded?

    Rallybio was founded in 2018.

  • Who are Rallybio key executives?

    Rallybio's key executives are Jeffrey Fryer and Steve Uden.

  • How many employees does Rallybio have?

    Rallybio has 28 employees.

  • Who are Rallybio competitors?

    Competitors of Rallybio include Oncologie, Lion TCR and Veloxis Pharmaceuticals.

  • Where is Rallybio headquarters?

    Rallybio headquarters is located at 234 Church Street, Suite 1020, New Haven.

  • Where are Rallybio offices?

    Rallybio has offices in New Haven and Farmington.

  • How many offices does Rallybio have?

    Rallybio has 2 offices.